• ASB3 Targets MAVS to Suppress Antiviral Immunity

  2026-08-24

  The 2024 Cell Death & Differentiation study identifies ASB3 as an inducible E3 ubiquitin ligase that weakens RNA-virus sensing by promoting K48-linked ubiquitination and proteasomal degradation of MAVS at K297. Genetic, virological, biochemical, and animal experiments connect this molecular event to reduced TBK1–IRF3 signaling, impaired type I interferon production, and greater susceptibility to influenza infection.

• One-step TUNEL Cy5 Apoptosis Detection Kit Guide

  2026-08-24

  Connect DNA-fragmentation readouts to drug-response experiments in cultured cells, flow cytometry, and tissue sections. This practical guide shows how to use a far-red TUNEL workflow to strengthen studies of TKI resistance while avoiding overinterpretation of apoptosis signals.

• 5-hme-dCTP for 5hmC Assay Design

  2026-08-23

  Use 5-hme-dCTP as a defined polymerase substrate, synthetic control, and assay-development reagent for mechanistic epigenetics. Its strongest value is in connecting controlled in vitro chemistry with native 5hmC mapping, including context-dependent studies of plant drought responses.

• Microfluidic Peptide/RNA Complexes for Pulmonary Delivery

  2026-08-22

  This 2025 study evaluates microfluidically prepared complexes of RNA with the cationic peptides LAH4-L1 and PEG12KL4 for nebulised pulmonary delivery. Its central finding is that vibrating-mesh aerosolisation generated inhalable droplets while preserving RNA binding and in vitro transfection performance, supporting peptide vectors as candidates for lung-directed siRNA and mRNA delivery.

• Rational Design of IR-1061 NIR-II Liposomes

  2026-08-22

  The reference study shows that IR-1061 performance in NIR-II imaging depends not only on the fluorophore itself, but also on liposome charge, loading, and confinement. By optimizing these formulation variables, the authors developed IR1061-ALP-N3 for high-resolution systemic angiography and sustained vascular fluorescence in mice.

• SU5416 (Semaxanib) VEGFR2 Workflow Guide

  2026-08-21

  SU5416 (Semaxanib) enables controlled studies of VEGFR2 signaling, endothelial responses, tumor vascularization, and selected immune effects. This workflow-oriented guide shows how to separate target engagement from model-specific outcomes, including the important finding that pneumonectomy plus SU5416 does not reliably create severe pulmonary hypertension in C57BL/6 mice.

• Tetramethylrhodamine ethyl ester perchlorate Guide

  2026-08-20

  Use TMRE as a live-cell readout of mitochondrial membrane potential, then combine imaging or flow cytometry with ROS and apoptosis measurements to resolve mechanism. This practical guide shows how C8197 can support toxin studies, mitochondrial dysfunction in disease research, and quantitative assay troubleshooting.

• Cy5-UTP for Structure-Aware RNA Assays

  2026-08-20

  Cy5-UTP enables direct fluorescent RNA probe synthesis while preserving a workflow for interrogating RNA structure and RNA–protein recognition. This article connects Cyanine 5-uridine triphosphate labeling with XIST–SPEN assay design, highlighting practical controls that broad FISH and array-focused protocols often overlook.

• Ceftolozane/Tazobactam: Evidence and Research Implications

  2026-08-19

  This review evaluates ceftolozane/tazobactam as an antipseudomonal cephalosporin and beta-lactamase inhibitor combination, integrating its mechanism, resistance profile, pharmacokinetics, pharmacodynamics, clinical evidence, and tolerability. Its main contribution is a clinically oriented synthesis showing how ceftolozane’s PBP activity and tazobactam-mediated beta-lactamase inhibition address important resistant gram-negative pathogens while retaining a practical renal dosing framework.

• Directed Differentiation of hiPSCs into Corneal Endothelium

  2026-08-19

  Diao and colleagues developed a two-stage, chemically defined, serum-free workflow that guides human induced pluripotent stem cells through a neural crest intermediate toward corneal endothelial cell-like cells. The study is especially informative because it uses temporally distinct TGF-β and Wnt/β-catenin signaling pathway modulation, providing a practical framework for reproducible lineage specification rather than relying on direct epithelial conversion.

• Cytochalasin B in Actin-Dependent Entry Assays

  2026-08-18

  Cytochalasin B (NSC 107658) is more than an actin-disrupting reagent: it can help distinguish cytoskeletal requirements from nonspecific loss of cell fitness. This evidence-led guide uses Spiroplasma infection in Drosophila S2 cells to build stronger entry, motility, and drug-discovery assays.

• KDM3A–METTL16–PDK1 Axis Drives TKI Resistance

  2026-08-18

  The reference study identifies a coordinated epigenetic and post-transcriptional mechanism that elevates PDK1 and promotes resistance to gefitinib and osimertinib. Its findings position the KDM3A/METTL16/PDK1 axis as a mechanistic framework for studying acquired TKI resistance and as a potential source of biomarkers and combination-treatment strategies.

• Targeted mRNA Nanoparticles After Ischemic Stroke

  2026-08-17

  Gao and colleagues developed M2 microglia-targeting lipid nanoparticles that deliver interleukin-10 mRNA to ischemic brain tissue, establishing a feedback loop that reinforces anti-inflammatory microglial polarization. Across transient and permanent mouse stroke models, the approach reduced neuroinflammation, improved blood–brain barrier integrity, limited neuronal apoptosis, and alleviated neurological deficits, with reported activity when treatment began up to 72 hours after stroke.

• XAV-939: Tankyrase Logic for Translational Wnt Research

  2026-08-17

  XAV-939, also known as NVP-XAV939, offers a mechanistically defined way to interrogate tankyrase-dependent control of Wnt/β-catenin signaling. This thought-leadership article connects axin stabilization to cancer research, fibrotic disease research, and bone biology while outlining practical validation, translational limitations, and next-generation study design.

• GSH-Responsive MOF Photothermal-Immunotherapy

  2026-08-16

  Hao and colleagues developed ICG-MOF-SS-AUNP12, a glutathione-responsive metal–organic framework that combines near-infrared photothermal ablation with PD-1/PD-L1 checkpoint blockade for melanoma treatment. The study shows how stimulus-responsive release and immune activation can address limitations of single-agent photothermal therapy, while also identifying experimental considerations for translating the platform to other tumor models.

8358 records 7/558 page Previous Next First page 上5页 678910 下5页 Last page